Outcome Capital announced UCB Pharma has acquired privately held Beryllium Discovery.
Beryllium, a specialized drug discovery contract research organization (CRO), provides research services and engages in collaborations with leading pharmaceutical, innovative biotechnology, and academic partners based on its innovative drug discovery platform. Outcome Capital served as the exclusive strategic and financial advisor to Beryllium for the transaction.
Using a biology-first, target-centric approach, Beryllium has developed deep expertise in protein engineering, expression and purification, as well as functional biology and protein structure designed to find unique therapeutic drugs. The company has had a long partnership with UCB, a developer of treatments for severe neurological and immunological diseases, which previously acquired a minority stake in Beryllium.
Beryllium’s scientific team has published more than 150 journal articles and contributed more than 1% of all structures deposited in the public protein data bank.
“We are proud of our scientific achievements, and this deal is the ultimate recognition of our success. Our talented partners at UCB are in a great position to further build Beryllium’s platform and use it to bring more innovation to their high-value discovery program,” Johan Pontin, CEO of Beryllium Discovery said. “This is also a great outcome for all Beryllium stakeholders, and I was very impressed with Outcome Capital’s ability to make it happen.”